Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthias Evert

Showing results (111-120 of 228) with videos related to

Pageof 23
Sort By:
Bladder Cancer (Amsterdam, Netherlands)|August 22, 2017
Increased Proliferation as Independent Predictor of Disease Recurrence in Initial Stage pTa Urothelial Bladder CancerJohannes Breyer, Sanzhar Shalekenov, Atiqullah Aziz, et al.
Hepatology (Baltimore, Md.)|October 14, 2011
AKT (v-akt murine thymoma viral oncogene homolog 1) and N-Ras (neuroblastoma ras viral oncogene homolog) coactivation in the mouse liver promotes rapid carcinogenesis by way of mTOR (mammalian target of rapamycin complex 1), FOXM1 (forkhead box M1)/SKP2, and c-Myc pathwaysCoral Ho, Chunmei Wang, Sandra Mattu, et al.
Hepatology (Baltimore, Md.)|January 25, 2012
V-AKT murine thymoma viral oncogene homolog/mammalian target of rapamycin activation induces a module of metabolic changes contributing to growth in insulin-induced hepatocarcinogenesisMatthias Evert, Diego F Calvisi, Katja Evert, et al.
Scientific Reports|February 10, 2016
Co-activation of AKT and c-Met triggers rapid hepatocellular carcinoma development via the mTORC1/FASN pathway in miceJunjie Hu, Li Che, Lei Li, et al.
Hepatology (Baltimore, Md.)|April 12, 2011
Activation of v-Myb avian myeloblastosis viral oncogene homolog-like2 (MYBL2)-LIN9 complex contributes to human hepatocarcinogenesis and identifies a subset of hepatocellular carcinoma with mutant p53Diego F Calvisi, Maria M Simile, Sara Ladu, et al.
Cancers|July 7, 2019
Combined Treatment with MEK and mTOR Inhibitors is Effective in In Vitro and In Vivo Models of Hepatocellular CarcinomaXianqiong Liu, Junjie Hu, Xinhua Song, et al.
Hepatology (Baltimore, Md.)|August 23, 2014
4EBP1/eIF4E and p70S6K/RPS6 axes play critical and distinct roles in hepatocarcinogenesis driven by AKT and N-Ras proto-oncogenes in miceChunmei Wang, Antonio Cigliano, Lijie Jiang, et al.
JCO Precision Oncology|September 27, 2021
<i>STRN-ALK</i> Fusion in a Case of Malignant Peritoneal Mesothelioma: Mixed Response to Crizotinib, Mode of Resistance, and Brigatinib Sequential TherapyValeria Gerthofer, Alexander Scheiter, Florian Lüke, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|August 15, 2024
ARX, PDX1, ISL1, and CDX2 Expression Distinguishes 5 Subgroups of Pancreatic Neuroendocrine Tumors With Correlations to Histology, Hormone Expression, and OutcomeElisa Moser, Ayako Ura, Loreen Vogel, et al.
Gut|November 4, 2020
Cabozantinib-based combination therapy for the treatment of hepatocellular carcinomaRunze Shang, Xinhua Song, Pan Wang, et al.
Pageof 23

Showing results (111-120 of 228) with videos related to

Sort By:
Pageof 23
Bladder Cancer (Amsterdam, Netherlands)|August 22, 2017
Increased Proliferation as Independent Predictor of Disease Recurrence in Initial Stage pTa Urothelial Bladder CancerJohannes Breyer, Sanzhar Shalekenov, Atiqullah Aziz, et al.
Hepatology (Baltimore, Md.)|October 14, 2011
AKT (v-akt murine thymoma viral oncogene homolog 1) and N-Ras (neuroblastoma ras viral oncogene homolog) coactivation in the mouse liver promotes rapid carcinogenesis by way of mTOR (mammalian target of rapamycin complex 1), FOXM1 (forkhead box M1)/SKP2, and c-Myc pathwaysCoral Ho, Chunmei Wang, Sandra Mattu, et al.
Hepatology (Baltimore, Md.)|January 25, 2012
V-AKT murine thymoma viral oncogene homolog/mammalian target of rapamycin activation induces a module of metabolic changes contributing to growth in insulin-induced hepatocarcinogenesisMatthias Evert, Diego F Calvisi, Katja Evert, et al.
Scientific Reports|February 10, 2016
Co-activation of AKT and c-Met triggers rapid hepatocellular carcinoma development via the mTORC1/FASN pathway in miceJunjie Hu, Li Che, Lei Li, et al.
Hepatology (Baltimore, Md.)|April 12, 2011
Activation of v-Myb avian myeloblastosis viral oncogene homolog-like2 (MYBL2)-LIN9 complex contributes to human hepatocarcinogenesis and identifies a subset of hepatocellular carcinoma with mutant p53Diego F Calvisi, Maria M Simile, Sara Ladu, et al.
Cancers|July 7, 2019
Combined Treatment with MEK and mTOR Inhibitors is Effective in In Vitro and In Vivo Models of Hepatocellular CarcinomaXianqiong Liu, Junjie Hu, Xinhua Song, et al.
Hepatology (Baltimore, Md.)|August 23, 2014
4EBP1/eIF4E and p70S6K/RPS6 axes play critical and distinct roles in hepatocarcinogenesis driven by AKT and N-Ras proto-oncogenes in miceChunmei Wang, Antonio Cigliano, Lijie Jiang, et al.
JCO Precision Oncology|September 27, 2021
<i>STRN-ALK</i> Fusion in a Case of Malignant Peritoneal Mesothelioma: Mixed Response to Crizotinib, Mode of Resistance, and Brigatinib Sequential TherapyValeria Gerthofer, Alexander Scheiter, Florian Lüke, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|August 15, 2024
ARX, PDX1, ISL1, and CDX2 Expression Distinguishes 5 Subgroups of Pancreatic Neuroendocrine Tumors With Correlations to Histology, Hormone Expression, and OutcomeElisa Moser, Ayako Ura, Loreen Vogel, et al.
Gut|November 4, 2020
Cabozantinib-based combination therapy for the treatment of hepatocellular carcinomaRunze Shang, Xinhua Song, Pan Wang, et al.
Pageof 23